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Abstract
Background: Diabetes prevalence increases globally with severe consequences for afflicted
individuals and societies. Data on diabetes incidence and diabetes related mortality on a population
level are, however, scarce. As an alternative to dedicated studies it has been suggested to use
pharmacoepidemiological databases that are readily available, at least in the Nordic countries.
Methods: For all 470,000 inhabitants in Funen County, Denmark, in the period 1992–2003, data
on gender, date of birth, death and migration to and from the county, and any filled prescriptions
of an anti-diabetic medication was obtained from the Odense Pharmaco-Epidemiological Database.
Results: Prevalence odds for use of an anti-diabetic medication rose annually 3.5% (95%
confidence interval: 3.1%, 3.9%) for females, 4.5% (4.0%, 4.9%) for males. Corresponding incidence
rates annually rose 4.8% (3.8%, 5.8%) for females, 4.5% (3.5%, 5.4%) for males. Mortality rates
among treated annually declined 2.8% (1.4%, 4.1%) among females, 2.2% (0.9%, 3.5%) among males.
The disequilibrium in absolute numbers between incidence and mortality among treated was the
main driver for the increasing prevalence, while concurrent trends in incidence and diabetes related
mortality only marginally affected prevalence trends. Trend estimates were insensitive to varying
the length of the run-in period used for determining treatment status, except when using the naive
and methodologically flawed run-in period of variable length.
Conclusion: While pharmacoepidemiological databases provide a useful tool for monitoring
pharmacologically treated diabetes, a dedicated diabetes database covering all prevalents and
incidents is needed for a more detailed analysis of underlying causes and trends.
Background
The population epidemiology of diabetes mellitus is of
public health interest from several perspectives. Diabetes
has severe costs for afflicted patients, as it is a chronic life-
long disease characterized by excess mortality [1] and
high comorbidity with cardiovascular disease, nephropa-
Published: 21 February 2007
Population Health Metrics 2007, 5:2 doi:10.1186/1478-7954-5-2
Received: 29 September 2006
Accepted: 21 February 2007
This article is available from: http://www.pophealthmetrics.com/content/5/1/2
© 2007 Støvring et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Page 1 of 11
(page number not for citation purposes)
Population Health Metrics 2007, 5:2 http://www.pophealthmetrics.com/content/5/1/2thy and eye complications as prominent examples [2].
Diabetes has a high impact on general populations, in
particular in Western societies: The prevalence increases
with age and reaches a level of about 10% at the age of 60
years and above in most populations [1]. Diabetes preva-
lence has been found to increase in all age groups during
the last 20 years, and WHO has estimated that the number
of diabetics in the world will more than double within the
next 25 years from about 170 million in 2000 to about
366 million in year 2030 [3]. This increase of about 3.1%
per year in prevalence has been claimed to fulfill the crite-
ria for an epidemic, particularly of type 2 diabetes [4,5].
Others have claimed that an increase in prevalence alone
cannot be taken as proof of an ongoing epidemic [6].
Also, prevention of diabetes (in particular type II) has
attracted much attention with focus on the relation
between lifestyle and risk of becoming a diabetic, and sev-
eral countries have set up large scale prevention programs.
From a medical point of view, the secondary prophylaxis
is of high interest with focus on improving life quality and
survival with diabetes through health initiatives ranging
from motivational intervention, monitoring of disease, to
new pharmaceutical treatments.
At the heart of these perspectives is the need to obtain
valid and current estimates on trends in diabetes inci-
dence, prevalence and mortality. Such estimates are, how-
ever, typically costly to obtain on a general population
level, and are hence often missing. In this context, it has
been suggested that pharmacoepidemiological databases
could be used to study the dynamics of the diabetes epi-
demiology for large, well-defined populations, even when
the databases only contain information on filled prescrip-
tions [7]. A prime advantage of using pharmacoepidemi-
ological databases for such epidemiological descriptions
is obviously that the data are readily available. But,
although other studies have shown that diabetes preva-
lence may be reliably estimated from total consumption
data [8-10], the use of individual claims data for a more
detailed analysis of trends in incidence, prevalence and
mortality has so far received less attention. Such an
approach is not without its challenges, since both date of
onset as well as true, current disease status are not
recorded in this type of pharmacoepidemiological data-
bases. Misclassification is thus a potential problem, and
the type of potential bias introduced by different strategies
for determining treatment status at any given point in
time must be carefully considered. Indeed, intuitively
attractive approaches may introduce strong biases when
studying calendar time trends, as discussed below.
Although we update and extend previously published
results on the epidemiology of diabetes in the Funen pop-
ulation [7], the primary objective of this paper is method-
ological. First, we investigate the impact of different
choices of run-in periods, as this is a crucial methodolog-
ical issue in many pharmacoepidemiological studies. Sec-
ondly, we study the relative contributions of current
trends in incidence and mortality to the concurrent,
observed rise in diabetes prevalence, ie. we focus on the
question: Can prevalence rise while contemporary inci-
dence and mortality rates remain constant?
Methods
Odense Pharmaco-Epidemiologic Database (OPED) was
used as data source. OPED contains information on all
redemptions of subsidized and prescribed drugs at com-
munity pharmacies in the county of Fyn, Denmark [11]
since 1992. It is a copy of the exhaustive electronic register
maintained for administering all subsidies to pharmacies
as well as prescribing physicians in the county. Informa-
tion on the drug is entered directly into the electronic reg-
ister when a prescription is processed and dispensed –
which yields very high validity [12] – and in accordance
with the Anatomical Therapeutical Chemical (ATC) classi-
fication system [13]. All anti-diabetic drugs are character-
ized by the first three characters being A10, insulin by
A10A, oral anti-diabetics by A10B.
OPED contains information on birth date, gender, migra-
tion and death for all subjects living within the county in
the period January 1, 1992 to December 31, 2003 in
accordance with the Danish Central Person Register. All
records allow unique tracking of individuals by means of
the nationwide Civil Registration Number.
For each individual we determined presence and treat-
ment status with respect to use of anti-diabetic medica-
tions on January 1 of each calendar year (the index date).
We defined treatment status based on a previous run-in
period's recordings of anti-diabetic drug dispensing, ie. if
a subject had at least one prescription within the run-in
period, the person was considered treated at the index
date. Consequently, for each calendar year we excluded all
who immigrated into Fyn during the run-in period, since
we could not determine treatment status with certainty for
immigrants without an observed redemption.
For those present at the index date and with a sufficient
run-in period, we computed annual counts of these enti-
ties: prevalence (P), incidence (I), treatment cessation
(C), deaths among all non-prevalents (D0), deaths among
prevalents (D1), and deaths among incidents (DInc). An
individual was considered prevalent on the index date if a
redemption was observed in the associated run-in period.
Incidence was defined as the number of subjects having a
redemption in the year of interest, but not in the run-in
period. Mortality counts were number of deaths in the
year of interest stratified on prevalence status at the index
date. Among those prevalent at the index date we defined
treatment cessation as having been observed for a periodPage 2 of 11
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any new redemptions and which overlapped the index
date. In a sub-analysis of the annual transitions between
treatment states (treated or not), we further subdivided
the number of subjects who had discontinued treatment
into two groups: Those who re-initiated treatment within
the calendar year, and those who did not.
For incidence and mortality among non-prevalents and
prevalents, respectively, we computed rates based on
counts and time at risk for the event in question. Time at
risk was defined as time from index date to either event or
censoring by migration, death, or end of year, whichever
was first. Relative mortalities were obtained by comparing
mortality rates among prevalents to rates among non-
prevalents.
In the sub-analyses of insulin and oral anti-diabetic med-
ications, only redemptions of the specific type were con-
sidered; for example, all redemptions of oral anti-diabetic
agents were ignored when restricting the analysis to insu-
lin.
Choosing the length of the run-in period is crucial in this
study, as in most pharmacoepidemiological studies, since
rates of exclusion must be balanced with misclassifica-
tion. For the fixed run-in periods we did two separate
analyses with lengths of one and two years, respectively.
The length of one year allows comparison with previously
published results [7], but we found it to be inadequate for
accommodating a change in the Danish subsidy system
taking place in 2000. We thus report on the effects of this
change and provide estimates based on a two years run-in
period, as these are unaffected by the switch. For illustra-
tive purposes we also present estimates based on increas-
ing the run-in period with calendar time, although these
are invalid as they introduce time-dependent misclassifi-
cation.
As trends in observed incidence of treatment initiation
both depends on the true trend in disease incidence as
well as trends in detection and tendency to initiate phar-
macological treatment, we conducted a sensitivity analy-
sis. Within each year we assume that there is an unknown
incidence proportion with an annual trend ρ. Further
assume that there is a detection probability πY, ie. of tran-
sition from undiagnosed to becoming diagnosed and ini-
tiating pharmacological treatment given that one
becomes diabetic. We assumed that π1994 was 60%. Note
that results of the sensitivity analysis with respect to trends
are virtually insensitive to the actual level of detection, so
this choice is not crucial. For changes in this probability
we assumed that they were in the range from a decline of
10 percentage points to an increase of 20 percentage
points from 1994 to 2003, ie. that detection proportions
in 2003 ranged from 50% to 80%. This corresponds to
annual changes of -2.0% to 3.2% in detection propor-
tions, ie. a ratio θ of 0.980 to 1.032 between subsequent
years. The annual trend ρ in true incidence can now be
related to the observed trend φ in incidence of treatment
by the following formula
We present graphs showing the relationship between
trends in true incidence and the observed trend in treat-
ment incidence when detection proportions vary.
We finally investigated the extent to which the rise in prev-
alence could be explained by concurrent trends in inci-
dence, mortality among treated and cessation rates,
respectively. We did so by comparing the observed annual
prevalences to projections based on fixing age-specific
rates of incidence, mortality and cessation among treated
to their values in 1994. Alternatively, incidence alone was
fixed to its level in 1994 to study the isolated impact of a
trend in incidence.
Statistical analysis
Annual incidence, prevalence and mortality rates were
determined within four age categories stratified by sex.
Annual trend estimates were obtained from regression
analysis with year and age categories (cut points at 15, 25,
..., 85) as covariates stratified on gender. Logistic regres-
sion was employed for analyzing prevalence, Poisson
regression for incidence and mortality rates. In the analy-
ses of prevalence and incidence, correlations among indi-
vidual's outcomes in subsequent years where allowed for
by using robust standard errors [14,15]. For prevalence
the trend was estimated as a linear trend on the log-odds-
ratio scale, whereas trends in both incidence and mortal-
ity were estimated as linear trends on a log-rate-ratio scale.
Cessation rates were not analyzed for trends as they are
not of primary interest and in any case estimates would be
based on small numbers. Estimates of age-adjusted
annual trends with 95%-confidence intervals are given as
odds-ratios and rate-ratios. All analyses were performed in
Stata 8 [16].
Results
Basic characteristics of the studied population are pre-
sented in Tables 1 and 2 using a two year run-in period.
Population size is almost constant with only a slight
increase while the age-composition changes with an
increase in the middle-aged group (40–64 years) and
among children (<15), and a decline among younger
adults (15–39 years). For both sexes, and in all age-
groups, prevalence increases, most distinctly among mid-
dle-aged, as does incidence, with males aged 15–39 years
ρ φ
θ
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untreated across all age groups declines over the study
period, in particular among males above age 65. Mortality
among treated increases in absolute numbers, but
declines relatively when compared to the concurrent
increase in prevalence. A graphical presentation of relative
measures is given in Figure 1.
Careful inspection of Table 2 reveals that book-keeping
with respect to prevalence does not tally in the following
sense: The prevalence of a given year does not correspond
to the prevalence plus incidence minus deaths among
treated of the previous year. What is missing is the count
of apparent treatment cessations. In Table 3 the book-
keeping is carried out including the annual number of
treatment cessations and correcting the number of deaths
among the prevalents accordingly. The final column of
Table 3 shows that the discrepancy between the predicted
prevalence according to this book-keeping principle and
the actually recorded prevalence is small. The difference is
due to censoring induced by migration, since the cohort is
open.
Table 4 gives estimates of age- and sex-adjusted trends.
Both prevalence and incidence trend estimates are posi-
tive and statistically significant, regardless of gender, anti-
diabetic drug type, and length of run-in. Mortality
declines among treated (except for males with respect to
insulin when using a two year run-in period) over the
study period, and notably also relative to the non-treated
population.
Methodological considerations I: Length of run-in
Table 5 shows the annual count of patients defined as hav-
ing discontinued treatment based on a gap of either one
year or two years between last redemption in the run-in
period and first redemption in the following year. Using a
gap of one year leads to a peak in 2001 reflecting a change
Table 1: Characteristics of source population
Females Age
<15 15 – 39 40 – 64 65 >
Year Size P I D1 D0 Size P I D1 D0 Size P I D1 D0 Size P I D1 D0
1994 34,514 10 0 0 8 73,456 339 43 0 39 71,305 967 147 12 318 45,884 2,049 226 197 2,081
1995 34,806 6 3 0 7 72,593 343 33 2 34 72,133 1,046 146 18 313 45,862 2,069 217 234 2,156
1996 35,398 8 20 0 8 71,502 338 46 0 39 73,031 1,099 163 11 325 45,702 2,056 271 196 2,133
1997 35,985 23 11 0 6 70,541 345 27 0 33 73,798 1,149 154 16 311 45,625 2,145 226 219 2,121
1998 36,919 32 7 0 6 69,832 323 29 2 23 74,896 1,221 139 16 314 45,439 2,185 254 211 2,043
1999 37,260 35 9 0 6 69,089 303 39 0 22 75,568 1,234 178 20 323 45,472 2,264 260 206 2,171
2000 37,627 38 8 0 7 68,040 320 41 1 28 76,436 1,293 205 23 310 45,407 2,346 267 190 2,078
2001 38,124 40 10 0 7 66,874 330 49 1 24 77,218 1,412 213 27 308 45,392 2,430 275 187 2,057
2002 38,335 43 12 0 6 66,007 341 45 0 36 77,832 1,500 226 22 276 45,571 2,562 298 219 2,207
2003 38,420 48 11 0 4 65,147 360 78 2 27 78,712 1,620 253 26 307 45,561 2,656 314 221 2,025
Males Age
<15 15 – 39 40 – 64 65 >
Year Size P I D1 D0 Size P I D1 D0 Size P I D1 D0 Size P I D1 D0
1994 36,066 12 2 0 12 77,830 408 49 1 83 71,598 1,424 227 52 478 33,454 1,658 241 203 1,974
1995 36,486 9 3 0 10 76,891 419 45 2 102 72,555 1,525 212 39 451 33,364 1,714 209 189 2,030
1996 37,173 7 26 0 5 75,486 415 55 6 82 73,548 1,597 250 28 448 33,209 1,761 232 197 2,057
1997 37,857 31 5 0 9 74,528 423 36 2 87 74,466 1,739 248 37 455 32,994 1,811 215 203 1,866
1998 38,839 36 3 0 13 73,694 425 40 2 65 75,668 1,826 292 44 471 32,997 1,887 236 192 1,857
1999 39,368 36 8 0 9 72,550 430 42 6 86 76,434 1,956 286 44 455 33,087 1,974 223 213 1,890
2000 39,741 41 14 0 12 71,316 422 41 3 67 77,268 2,103 315 52 463 33,137 2,014 253 184 1,780
2001 39,882 46 13 1 12 70,321 436 51 1 47 77,965 2,227 340 48 444 33,425 2,158 237 226 1,804
2002 40,034 49 11 0 12 69,106 455 64 2 67 78,888 2,414 389 59 477 33,655 2,213 270 228 1,723
2003 40,093 47 6 0 10 68,146 466 43 3 62 79,606 2,583 401 59 469 34,163 2,357 333 230 1,657
Size of population, prevalence, incidence, and mortality with respect to use of anti-diabetic drugs, Fyn County, Denmark, 1994–2003. Size is the 
size of the population on January 1, 1993–2003, where subjects migrating into the capture area in the preceding year are ignored. P is the count of 
prevalent subjects at January 1 of the given year. I is the count of incident subjects during the calendar year. D1 is the count of deaths during the 
year among subjects prevalent at the beginning of the year. D0 are deaths among non-prevalents in the year.Page 4 of 11
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have stockpiled in early 2000 followed by a longer period
without redemptions. This effect is smoothed out by using
a gap of two years, i.e. the two year run-in period defines
treatment status without obvious time-dependent mis-
classification.
As seen from Table 4 there is, however, virtually no differ-
ence in trend estimates of prevalence, incidence and mor-
tality, whether we choose a one or two year year long run-
in period. Only exception is for incidence, and this is a
result of a high incidence in 1993. With a two year run-in
period, we are forced to omit this year when estimating
trends, and hence the trend is attenuated.
If, however, we were to naively use all available informa-
tion prior to a given index date to determine treatment
status, trend estimates of prevalence become markedly
increased, and trend estimates for incidence decreased.
The relative biases of this naive approach range from
20%–40% for these parameters. Trends in mortality are
unaffected by using a variable length run-in period.
Methodological considerations II: Trends in detection 
proportions
In Figure 2 we present the results of our sensitivity analy-
sis. As observed trends in incidence we used the estimated
trends of 1.048 (1.03.8, 1.058) for females, and 1.045
(1.035, 1.054) for males. Even for unrealistic large
changes in detection proportions the trend in true inci-
dence does not vanish.
Methodological considerations III: Anatomy of an 
"epidemic"
Above we observed an increase in prevalence and inci-
dence accompanied by a decrease in mortality among
treated. A common interpretation would be to explain the
trend in prevalence with the concurrent trends in inci-
dence and mortality. This would however be an oversim-
plification if prevalence could rise while incidence and
mortality rates remained constant. To examine whether
this actually occurred during the study period, we com-
pared the observed number of prevalents over the study
period to the number of prevalents that would be pre-
dicted if incidence, mortality among treated, and cessa-
tion rates all had remained constant at their level in 1994.
Alternatively, we only fixed incidence rate at its 1994-
level, while allowing mortality among treated and cessa-
tion rates to vary as observed. The resulting projections are
shown in Figure 3.
For the period 1995–1999, agreement is very good
between observed and projected prevalence among
females, while poorer among males. For both genders the
discrepancy increases from year 2000. Keeping only inci-
dence fixed improves agreement between observed and
projected prevalence substantially, in particular among
men, ie. for men the combined decline in mortality and
cessation explain more of the observed rise in prevalence
than for women. The bulk of the rise in prevalence is thus
not due to contemporary changes in incidence or mortal-
ity rates, but to incident subjects outnumbering deaths
among treated and treatment cessations.
Discussion
Throughout the study period, prevalence of use of anti-
diabetic agents increased both in absolute and relative
terms, as well as within and across age strata. The corre-
sponding incidence also increased, while mortality
among treated declined, also relative to mortality among
untreated. This agrees with previous results [7], except
with respect to incidence.
Table 2: Characteristics of source population (totals for Table 1)
Females Males
Year Size P I D1 D0 Size P I D1 D0
1994 225,159 3,365 416 209 2,446 218,948 3,502 519 256 2,547
1995 225,394 3,464 399 254 2,510 219,296 3,667 469 230 2,593
1996 225,633 3,501 500 207 2,505 219,416 3,780 563 231 2,592
1997 225,949 3,662 418 235 2,471 219,845 4,004 504 242 2,417
1998 227,086 3,761 429 229 2,386 221,198 4,174 571 238 2,406
1999 227,389 3,836 486 226 2,522 221,439 4,396 559 263 2,440
2000 227,510 3,997 521 214 2,423 221,462 4,580 623 239 2,322
2001 227,608 4,212 547 215 2,396 221,593 4,867 641 276 2,307
2002 227,745 4,446 581 241 2,525 221,683 5,131 734 289 2,279
2003 227,840 4,684 656 249 2,363 222,008 5,453 783 292 2,198
Total size of population, prevalence, incidence, and mortality with respect to use of anti-diabetic drugs, Fyn County, Denmark, 1994–2003, cf. Table 
1. Size is the size of the population on January 1, 1993–2003, where subjects migrating into the capture area in the preceding year are ignored. P 
is the count of prevalent subjects at January 1 of the given year. I is the count of incident subjects during the calendar year. D1 is the count of deaths 
during the year among subjects prevalent at the beginning of the year. D0 are deaths among non-prevalents in the year.Page 5 of 11
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Prevalence, incidence and mortality estimates stratified by gender and age, Fyn County, Denmark, 1994–2003Figur  1
Prevalence, incidence and mortality estimates stratified by gender and age, Fyn County, Denmark, 1994–2003. Line-styles indi-
cate age-categories in years: — 0–14, - - 15–39, ... 40–64, -·- 65+.
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Population Health Metrics 2007, 5:2 http://www.pophealthmetrics.com/content/5/1/2The data used are generally of high validity, as they result
from automated registration of economic transaction
data; near complete coverage, except for medications
filled at a pharmacy outside the subjects residential
county, which for all drugs was found to not exceed 0.5%
[12]; the information on migration and vital statistics is
identical to the relevant subset of the registration at Statis-
tics Denmark.
The major limitation of the present study is its reliance on
drug redemptions. Obtaining a drug is not equivalent to
using it, and when used there is no observation of end of
use. Consequently, we investigated the impact of different
treatment classification rules and found that trend esti-
mates for prevalence, incidence, and mortality were
largely unaffected, except for the flawed principle of using
a run-in period of varying length.
Further, our estimates for prevalence, incidence, and mor-
tality by definition only concern subjects with treated dia-
betes, i.e. our results do not apply to undiagnosed
diabetics, nor to diabetics treated exclusively with diet.
These subjects are misclassified in the sense that they are
considered part of the general, non-diabetic population in
the present study. As all Danish citizens are covered by a
government funded health care plan, the annual cost of
medications for chronic diseases to be paid by a single
individual cannot exceed approximately DKK 3,600
(nearly USD 600) per year. In contrast to many other
countries one may therefore expect a rather limited
dependence of misclassification rates on social class and,
in particular, financial capacity. Other heterogeneities in
misclassification rates due to life style, attitudes to health
care, etc., may also exist, but like those due to financial
capacity and social class, we have little reason to assume
that they have changed substantially over the last decade
and could imply artificial time trends in incidence or prev-
alence. Especially, we did not identify the age trend in ces-
sation rates reported by Glynn et al in two studies [17,18].
Only for the youngest age-groups were cessation rates
slightly elevated, and this may indicate that misclassifica-
tion may not so much depend on cost as on need and per-
ceived necessity of treatment.
The prevalence level of pharmacologically treated diabe-
tes found here is in line with other contemporary studies
in Denmark [19,20]. For the year 1996, Kristensen et al
[21] found that 71% of all patients diagnosed with type II
diabetes in Vejle County, Denmark, were treated pharma-
cologically. Further, Drivsholm et al [19] estimated from a
one year run-in period the number of pharmacologically
treated diabetes patients in Denmark on Dec 31, 1999, to
Table 3: Book-keeping for size of total prevalent population
Gender Year P I CNI CI D1 DInc Diff
Females 1994 3365 416 107 11 207 18
1995 3464 399 123 10 248 12 -3
1996 3501 500 109 12 206 22 9
1997 3662 418 94 7 230 23 -24
1998 3761 429 114 9 225 19 5
1999 3836 486 91 11 223 14 -15
2000 3997 521 83 9 209 19 -11
2001 4212 547 92 8 213 15 -14
2002 4446 581 96 21 237 20 -8
2003 4684 656 84 15 244 24 -10
Males 1994 3502 519 94 5 254 23
1995 3667 469 109 6 226 18 -6
1996 3780 563 96 12 228 31 -21
1997 4004 504 106 7 239 18 -15
1998 4174 571 105 12 235 26 11
1999 4396 559 97 11 261 22 -9
2000 4580 623 80 17 235 26 -17
2001 4867 641 96 18 274 21 -21
2002 5131 734 97 25 288 27 -7
2003 5453 783 111 15 283 39 -27
Bookkeeping for size of total prevalent population with respect to anti-diabetic treatment, Fyn County, Denmark, 1994–2003. P is prevalence on 
Jan 1 of the given year, I is number of incident subjects, CNI is number of persons having discontinued treatment without re-initiation in the given 
year, CI is number of persons having discontinued treatment who re-initiated treatment within the given year, D1 is number of deaths among 
treated, and DInc is number of incident subjects dying before the end of the year. Diff for year Y is PY - (PY-1 + IY-1 - CNI, Y-1 - D1,Y-1 - DInc, Y-1), ie. 
difference between observed and predicted prevalence. Note, that CI does not enter into the computation of Diff since these subjects both leave 
and re-enter the prevalent pool of subjects in the same year.Page 7 of 11
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identified diabetics, estimated to about 130,000 on the
same date. Interestingly, Drivsholm et al also found that
their primary data sources on hospital discharge diagno-
sis, measurement of blood glucose, and diabetic foot care,
were only able to identify approximately 80%–90% of
patients treated pharmacologically for diabetes, indicat-
ing the lack of a single data source with complete cover-
age. In short, it appears reasonable to consider the
proportion of pharmacologically treated diabetes patients
constant across the study period at about 75%, and to
expect the estimated trends in prevalence of pharmacolog-
ically treated diabetes to be valid for the entire diabetes
population. Regardless, we suggest our results to be of
genuine public health interest in themselves, as they per-
tain to that group of diabetics which must generally be
considered most severely afflicted, and thus requiring
most care.
A third consequence of relying on a pharmacoepidemio-
logical database is the inability to control for date of diag-
nosis in the analysis. In particular, in the analysis of
mortality among treated we could not account for dura-
tion of disease, and part of the explanation for the appar-
ently decreasing mortality could be earlier treatment of
patients with less severe diabetes.
The trend in incidence identified in this study was compa-
rable to the one found for the period 1993–1999,
reported in [7], although slightly attenuated. The attenua-
tion occurred both because the year 1993 was excluded in
the present study using a two year run-in period, and
because incidence began a steeper increase in 2000. Com-
bined with the enlarged sample size due to a longer study
period, this made the trend statistically significant. The
increase in incidence observed after year 2000 could hall-
mark the onset of a true diabetes epidemic, possibly
reflecting an impact from a sustained obesity epidemic on
onset of diabetes or other changes in lifestyle – although
postulating a general obesity epidemic in Denmark would
also appear to be an over-simplification according to a
recent study showing the existence of large heterogeneity
in obesity trends [22]. That an epidemic of diabetes could
be looming was supported by the finding that fixing inci-
dence at its level in 1994 could predict prevalence with
Table 5: Discontinuation of anti-diabetic treatment
Females Males
One year gap Two years gap One year gap Two years gap
Year n % n % n % n %
1993 198 6.6 174 5.6
1994 209 6.7 118 3.5 185 5.7 99 2.8
1995 199 6.2 133 3.8 188 5.5 115 3.1
1996 172 5.3 121 3.5 203 5.8 108 2.9
1997 188 5.5 101 2.8 196 5.2 113 2.8
1998 163 4.6 123 3.3 182 4.6 117 2.8
1999 135 3.7 102 2.7 166 4.0 108 2.5
2000 150 4.0 92 2.3 194 4.5 97 2.1
2001 282 7.1 100 2.4 375 8.2 114 2.3
2002 176 4.2 117 2.6 233 4.8 122 2.4
2003 189 4.2 99 2.1 250 4.9 126 2.3
Number of patients discontinuing anti-diabetic treatment, Fyn 
County, Denmark, 1994–2003. Discontinuation is defined as subjects 
with more than one or two years, respectively, without redemptions 
after a previous redemption. Percentage figures indicate relative 
proportion of the prevalent population who discontinues treatment.
Table 4: Trend estimates for incidence, prevalence, and mortality with respect to treatment with anti-diabetic agents
Run-in Treatment Gender Prevalence Incidence Mortality among treated Relative Mortality
One year All anti-diabetic F 1.036 1.032, 1.040 1.045 1.035, 1.055 0.973 0.959, 0.987 0.991 0.986, 0.995
M 1.044 1.040, 1.048 1.045 1.036, 1.054 0.974 0.961, 0.987 0.977 0.973, 0.982
Insulin F 1.036 1.030, 1.043 1.048 1.033, 1.064 0.977 0.955, 1.000 0.990 0.986, 0.994
M 1.045 1.039, 1.050 1.067 1.053, 1.082 1.000 0.976, 1.023 0.977 0.973, 0.981
Oral antidiab. F 1.045 1.039, 1.051 1.052 1.042, 1.059 0.969 0.953, 0.986 0.992 0.987, 0.996
M 1.052 1.046, 1.058 1.049 1.040, 1.058 0.959 0.943, 0.974 0.979 0.975, 0.984
Two year All anti-diabetic F 1.035 1.031, 1.039 1.048 1.038, 1.058 0.972 0.959, 0.986 0.990 0.986, 0.995
M 1.045 1.040, 1.049 1.045 1.035, 1.054 0.978 0.965, 0.991 0.978 0.974, 0.982
Insulin F 1.034 1.028, 1.040 1.049 1.033, 1.065 0.970 0.949, 0.992 0.990 0.986, 0.994
M 1.045 1.040, 1.051 1.065 1.050, 1.080 1.005 0.983, 1.028 0.977 0.973, 0.982
Oral antidiab. F 1.043 1.037, 1.049 1.055 1.045, 1.066 0.970 0.954, 0.987 0.991 0.987, 0.995
M 1.052 1.046, 1.058 1.050 1.040, 1.060 0.964 0.949, 0.979 0.980 0.976, 0.984
Variable All anti-diabetic F 1.046 1.042, 1.050 1.032 1.023, 1.041 0.974 0.962, 0.985 0.991 0.987, 0.995
M 1.053 1.049, 1.057 1.028 1.020, 1.036 0.973 0.962, 0.984 0.979 0.975, 0.982
Estimated age-adjusted, annual trends with 95%-confidence intervals for different categories of anti-diabetic drugs and with different lengths of run-
in periods, Fyn County, Denmark, 1992–2003. For prevalence the trend estimate is given as an odds-ratio based on logistic regression, whereas the 
remaining estimates are rate-ratios based on Poisson regression. The start of the study period depends on the length of run-in period used.Page 8 of 11
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Observed and true trends in incidence with respect to hypothesized changes in detection proportions from 1994 to 2003Figure 2
Observed and true trends in incidence with respect to hypothesized changes in detection proportions from 1994 to 2003. 
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Observed and predicted prevalences with respect to use of anti-diabetic drugs, Fyn County, Denmark, 1994–2003. Fixation of 
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Population Health Metrics 2007, 5:2 http://www.pophealthmetrics.com/content/5/1/2good precision until 2000, at which point the observed
prevalence started to outrun projected prevalence. It may,
however, be speculated that new diagnostic criteria, which
eased detection of new cases and were implemented in
1999 in Denmark, could have contributed to the observed
increase in incidence. For trends in incidence, our some-
what simplistic sensitivity analysis did however show that
even unrealistically large changes in detection propor-
tions could not remove the observed trend in incidence
entirely. One must however interpret these results cau-
tiously for two reasons. First the detection proportions are
by definition a simplified representation of the problem,
as they ignore the duration between true onset of disease
and initiation of pharmacological treatment. We are how-
ever not aware of any studies on this duration, let alone
trends in durations, which could be used to further qualify
our analysis, as existing studies only report prevalence of
undiagnosed diabetes [23]. Secondly, the detection pro-
portion covers both diagnosis and treatment initiation. It
might well be speculated that a trend towards earlier diag-
nosis could be offset by a smaller need for pharmacologi-
cal treatment among those with earlier diagnosis. For this
reason we believe that the studied range of changes in
detection proportions is probably too wide to only con-
tain realistic values. Note, that our considerations about
the relation of observed incidence, prevalence and mortal-
ity are independent of any assumptions about the causal
reason for a shift in incidence, be it a real increase in sub-
jects developing diabetes, a change in diagnostic proce-
dures, criteria or habits, or a change in treatment practices.
Whatever the explanation, the trend in incidence should
not be considered the primary reason for the concurrent
increase in prevalence. Instead, the primary explanation is
the annual surplus of subjects initiating treatment for dia-
betes compared to those leaving treatment which must be
considered a legacy of past diabetes incidence and treat-
ment. The surplus may be expected to increase further, if
current trends in incidence and mortality persist, and pro-
jections by WHO and others may thus severely underesti-
mate the true magnitude of diabetes prevalence ten to
twenty years from now, built as they are on stationary age-
specific incidence and mortality estimates [3].
In conclusion, we suggest that pharmacoepidemiologic
databases can provide useful information on current
trends in diabetes epidemiology if analyzed properly, and
at a much lower cost than ordinary studies. The major
drawback is the lack of insight in the underlying reasons
for any observed trends – an insight which can only be
obtained on a regular basis if a population-wide case data-
base collecting information on all incident and prevalent
diabetes cases is established.
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